Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

53%

8 trials in Phase 3/4

Results Transparency

0 of 15 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

5(35.7%)

N/A

3(21.4%)

Phase 1

3(21.4%)

Phase 3

3(21.4%)

14Total

Phase 4(5)

N/A(3)

Phase 1(3)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05104489Phase 1Completed

Dose-finding Study for AdimrSC-2f Vaccine

Role: lead

NCT04522089Phase 1Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

Role: lead

NCT04101435Phase 3Completed

Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

Role: lead

NCT01759654Phase 3Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects

Role: lead

NCT01514708Phase 4Completed

The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Role: lead

NCT01755364Phase 3Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old

Role: lead

NCT01356316Phase 4Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Role: lead

NCT01640691Phase 1Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Role: lead

NCT01356342Phase 4Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Role: lead

NCT01752881Phase 4Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Role: lead

NCT01355172Phase 4Completed

Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old

Role: lead

NCT01411358Not ApplicableCompleted

Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

Role: lead

NCT01007201Not ApplicableCompleted

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Role: lead

NCT01003145Not ApplicableCompleted

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Role: lead

NCT01354730Completed

A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women

Role: lead

All 15 trials loaded